Safety profile of RNAi nanomedicines.
The emerging class of RNA interference (RNAi) therapeutics is a fundamentally novel approach to treating human disease by enabling the pursuit of molecular targets considered "undruggable" by small molecules and traditional protein therapeutics. A key challenge toward realizing the full potential of this technology is the safe and efficient delivery of siRNA to target tissues. The physical chemical properties of siRNAs preclude passive diffusion across most cell membranes. For systemic administration, novel delivery systems are required to confer "drug-like" pharmacokinetic and pharmacodynamic properties. Engineered nanomaterials and the emerging field of nanomedicine are important drivers of turning the promise of RNAi therapeutics into reality. The current clinical progress of systemically administered siRNA therapeutics is reviewed, with special attention to the toxicity profiles associated with RNAi nanomedicines. As a case study, the preclinical development of ALN-VSP, the first lipid nanoparticle (LNP)-formulated siRNA therapeutic to be tested in cancer patients, is reviewed to broadly highlight some of the preclinical safety challenges and areas of investigation for "next generation" LNP systems.
Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA. sbarros@alnylam.com
Scott A
SA
Barros
Jared A
JA
Gollob
D000818:Animals; D006801:Humans; D008055:Lipids / Q000737:chemistry; D050997:Nanomedicine / Q000379:methods*; D053758:Nanoparticles; D009369:Neoplasms / Q000235:genetics / Q000628:therapy; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics
D008055:Lipids; D034741:RNA, Small Interfering